Scharf MB - Search Results

1

Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia.

Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW. Walsh JK, et al. Among authors: scharf mb. Clin Neuropharmacol. 2000 Jan-Feb;23(1):17-21. doi: 10.1097/00002826-200001000-00004. Clin Neuropharmacol. 2000. PMID: 10682226 Clinical Trial.

2

A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia.

Walsh JK, Vogel GW, Scharf M, Erman M, William Erwin C, Schweitzer PK, Mangano RM, Roth T. Walsh JK, et al. Sleep Med. 2000 Feb 1;1(1):41-49. doi: 10.1016/s1389-9457(99)00006-4. Sleep Med. 2000. PMID: 10733619

3

Eight weeks of non-nightly use of zolpidem for primary insomnia.

Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK, Ware JC. Walsh JK, et al. Sleep. 2000 Dec 15;23(8):1087-96. Sleep. 2000. PMID: 11145323 Clinical Trial.

4

A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.

Scharf MB, Roth T, Vogel GW, Walsh JK. Scharf MB, et al. J Clin Psychiatry. 1994 May;55(5):192-9. J Clin Psychiatry. 1994. PMID: 8071269 Clinical Trial.

5

Minimal rebound insomnia after treatment with 10-mg zolpidem.

Ware JC, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW. Ware JC, et al. Among authors: scharf mb. Clin Neuropharmacol. 1997 Apr;20(2):116-25. doi: 10.1097/00002826-199704000-00002. Clin Neuropharmacol. 1997. PMID: 9099463 Clinical Trial.

6

Zolpidem for persistent insomnia in SSRI-treated depressed patients.

Asnis GM, Chakraburtty A, DuBoff EA, Krystal A, Londborg PD, Rosenberg R, Roth-Schechter B, Scharf MB, Walsh JK. Asnis GM, et al. Among authors: scharf mb. J Clin Psychiatry. 1999 Oct;60(10):668-76. doi: 10.4088/jcp.v60n1005. J Clin Psychiatry. 1999. PMID: 10549683 Clinical Trial.

7

Quazepam, a new benzodiazepine hypnotic: intermediate-term sleep laboratory evaluation.

Kales A, Scharf MB, Soldatos CR, Bixler EO, Bianchi SB, Schweitzer PK. Kales A, et al. Among authors: scharf mb. J Clin Pharmacol. 1980 Apr;20(4):184-92. doi: 10.1002/j.1552-4604.1980.tb01694.x. J Clin Pharmacol. 1980. PMID: 6103903 Clinical Trial. No abstract available.

8

Lorazepam-efficacy, side effects, and rebound phenomena.

Scharf MB, Kales A, Bixler EO, Jacoby JA, Schweitzer PK. Scharf MB, et al. Clin Pharmacol Ther. 1982 Feb;31(2):175-9. doi: 10.1038/clpt.1982.27. Clin Pharmacol Ther. 1982. PMID: 6120058

9

Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group.

Fry J, Scharf M, Mangano R, Fujimori M. Fry J, et al. Int Clin Psychopharmacol. 2000 May;15(3):141-52. doi: 10.1097/00004850-200015030-00003. Int Clin Psychopharmacol. 2000. PMID: 10870872 Clinical Trial.

10

Dose-response studies of quazepam.

Kales A, Scharf MB, Bixler EO, Schweitzer PK, Jacoby JA, Soldatos CR. Kales A, et al. Among authors: scharf mb. Clin Pharmacol Ther. 1981 Aug;30(2):194-200. doi: 10.1038/clpt.1981.148. Clin Pharmacol Ther. 1981. PMID: 6113910

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters